Conceivable Life Sciences Appoints President and SVP of Commercial Operations Ahead of U.S. Launch of World's First Automation-Assisted IVF Lab
核心洞察
Conceivable Life Sciences (搜索) named Julie O'Shaughnessy as President and Vincent Payet as SVP of Commercial Operations & Partner Success to lead the U.S. commercial launch of its AURA (搜索) platform.
AURA (搜索) is the world's first automation-assisted IVF lab, designed to replace hundreds of operator-dependent manual steps with robotic precision under embryologist supervision.
The leadership appointments support Conceivable's partnership with IVI RMA Global (搜索), the world's leading fertility care organization, to deploy AURA (搜索) in the United States.
Conceivable Life Sciences (搜索), the company behind the world's first automation-assisted IVF lab, announced two senior leadership appointments on July 20, 2026, as it prepares for its U.S. commercial launch in partnership with IVI RMA Global (搜索), the world's leading fertility care organization. Julie O'Shaughnessy has been named President, and Vincent Payet has been appointed Senior Vice President of Commercial Operations & Partner Success.
The appointments reflect months of work assembling a leadership team with the operational and clinical partnership expertise needed to lower costs, expand access, and improve fertility outcomes through the company's AURA (搜索) platform.
Leadership with Deep Operational and Scientific Expertise
O'Shaughnessy joins Conceivable after building and scaling operations at some of the world's fastest-growing technology and biotechnology companies. Most recently, as Chief Operating Officer at Vivodyne (搜索), she helped build a next-generation drug discovery platform at the intersection of biology, automation, and AI. Previously, she held a senior leadership role at a leading bio-manufacturing company, helping scale the organization from startup to more than 2,000 employees and $2.5 billion in capitalized value. She was recruited to lead Conceivable's U.S. commercial launch and drive the company's global expansion strategy.
Payet joins from Ferring Pharmaceuticals (搜索), where he spent 13 years, most recently as CEO of Ferring North Latin America. He holds a PhD in Molecular and Cellular Biology and will lead clinical deployment and commercial partner relationship strategy as Conceivable scales globally.
"We built AURA (搜索) to standardize the IVF laboratory. Getting that right at scale requires a leadership team with real depth in operations and clinical partnerships, as well as conviction in the technology," said Alan Murray, CEO and Co-Founder of Conceivable Life Sciences (搜索). "Julie and Vincent have each already done, in their respective fields, what we now need to do together: turn a Nobel Prize-winning scientific breakthrough into a dependable, repeatable standard of care."
The AURA (搜索) Platform: Standardizing the IVF Laboratory
AURA (搜索) improves on hundreds of operator-dependent manual steps in the IVF laboratory with unmatched precision, under the supervision of embryologists. The platform is designed to improve consistency and precision across every step of the IVF laboratory workflow, with the goal of supporting better and more reproducible embryology results.
"Every patient deserves the same standard of care, regardless of which lab they're in or who is on shift that day. AURA (搜索) makes that possible technically. Julie and Vincent make it happen operationally," said Alejandro Chavez-Badiola, MD, Co-Founder & Chief Medical and Innovation Officer at Conceivable Life Sciences (搜索). "Building this team to support our IVI RMA launch is one of the most important steps we've taken as a company, and a critical foundation for what comes next."
Every cycle feeds a proprietary data flywheel designed to continuously improve outcomes. As the first major fertility network to implement Conceivable's technology, IVI RMA continues to lead the evolution of fertility care through more precise, consistent, and scalable treatment for patients worldwide.
Conceivable Life Sciences (搜索) is headquartered in New York with R&D centers in Barcelona, Guadalajara, and London.